vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Riot Platforms, Inc. (RIOT). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $152.8M, roughly 1.2× Riot Platforms, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -452.0%, a 465.3% gap on every dollar of revenue. On growth, Riot Platforms, Inc. posted the faster year-over-year revenue change (7.2% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-774.3M). Over the past eight quarters, Riot Platforms, Inc.'s revenue compounded faster (38.8% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Riot Platforms, Inc. is a leading U.S.-based enterprise focused on Bitcoin mining, operating multiple large-scale, energy-efficient data centers across North America. It also invests in blockchain infrastructure development and holds Bitcoin as a core long-term reserve asset, centering its business strategy around the digital asset ecosystem.
AMPH vs RIOT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $152.8M |
| Net Profit | $24.4M | $-690.7M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | -447.9% |
| Net Margin | 13.3% | -452.0% |
| Revenue YoY | -1.8% | 7.2% |
| Net Profit YoY | -35.7% | -606.3% |
| EPS (diluted) | $0.51 | $-1.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $152.8M | ||
| Q3 25 | $191.8M | $180.2M | ||
| Q2 25 | $174.4M | $153.0M | ||
| Q1 25 | $170.5M | $161.4M | ||
| Q4 24 | $186.5M | $142.6M | ||
| Q3 24 | $191.2M | $84.8M | ||
| Q2 24 | $182.4M | $70.0M | ||
| Q1 24 | $171.8M | $79.3M |
| Q4 25 | $24.4M | $-690.7M | ||
| Q3 25 | $17.4M | $104.5M | ||
| Q2 25 | $31.0M | $219.5M | ||
| Q1 25 | $25.3M | $-296.4M | ||
| Q4 24 | $38.0M | $136.4M | ||
| Q3 24 | $40.4M | $-154.4M | ||
| Q2 24 | $37.9M | $-84.4M | ||
| Q1 24 | $43.2M | $211.8M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | -447.9% | ||
| Q3 25 | 13.2% | 44.4% | ||
| Q2 25 | 24.2% | — | ||
| Q1 25 | 21.9% | -144.9% | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 29.8% | -143.3% | ||
| Q2 24 | 30.3% | -167.2% | ||
| Q1 24 | 27.9% | — |
| Q4 25 | 13.3% | -452.0% | ||
| Q3 25 | 9.0% | 58.0% | ||
| Q2 25 | 17.8% | 143.4% | ||
| Q1 25 | 14.8% | -183.6% | ||
| Q4 24 | 20.4% | 95.7% | ||
| Q3 24 | 21.1% | -182.1% | ||
| Q2 24 | 20.8% | -120.6% | ||
| Q1 24 | 25.1% | 267.1% |
| Q4 25 | $0.51 | $-1.89 | ||
| Q3 25 | $0.37 | $0.26 | ||
| Q2 25 | $0.64 | $0.58 | ||
| Q1 25 | $0.51 | $-0.90 | ||
| Q4 24 | $0.74 | $0.39 | ||
| Q3 24 | $0.78 | $-0.54 | ||
| Q2 24 | $0.73 | $-0.32 | ||
| Q1 24 | $0.81 | $0.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $233.5M |
| Total DebtLower is stronger | $608.7M | $840.8M |
| Stockholders' EquityBook value | $788.8M | $2.9B |
| Total Assets | $1.6B | $3.9B |
| Debt / EquityLower = less leverage | 0.77× | 0.29× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $233.5M | ||
| Q3 25 | $276.2M | $330.7M | ||
| Q2 25 | $231.8M | $255.4M | ||
| Q1 25 | $236.9M | $163.7M | ||
| Q4 24 | $221.6M | $277.9M | ||
| Q3 24 | $250.5M | $355.7M | ||
| Q2 24 | $217.8M | $481.2M | ||
| Q1 24 | $289.6M | $688.5M |
| Q4 25 | $608.7M | $840.8M | ||
| Q3 25 | $608.6M | $5.3M | ||
| Q2 25 | $607.7M | $5.3M | ||
| Q1 25 | $603.9M | $5.3M | ||
| Q4 24 | $601.6M | $584.6M | ||
| Q3 24 | $596.4M | $5.7M | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $2.9B | ||
| Q3 25 | $776.7M | $3.5B | ||
| Q2 25 | $757.5M | $3.3B | ||
| Q1 25 | $751.3M | $2.9B | ||
| Q4 24 | $732.3M | $3.1B | ||
| Q3 24 | $727.7M | $2.7B | ||
| Q2 24 | $713.3M | $2.6B | ||
| Q1 24 | $672.4M | $2.5B |
| Q4 25 | $1.6B | $3.9B | ||
| Q3 25 | $1.7B | $4.5B | ||
| Q2 25 | $1.6B | $4.3B | ||
| Q1 25 | $1.6B | $3.7B | ||
| Q4 24 | $1.6B | $3.9B | ||
| Q3 24 | $1.5B | $2.9B | ||
| Q2 24 | $1.5B | $2.7B | ||
| Q1 24 | $1.6B | $2.6B |
| Q4 25 | 0.77× | 0.29× | ||
| Q3 25 | 0.78× | 0.00× | ||
| Q2 25 | 0.80× | 0.00× | ||
| Q1 25 | 0.80× | 0.00× | ||
| Q4 24 | 0.82× | 0.19× | ||
| Q3 24 | 0.82× | 0.00× | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $-572.9M |
| Free Cash FlowOCF − Capex | $24.6M | $-774.3M |
| FCF MarginFCF / Revenue | 13.4% | -506.6% |
| Capex IntensityCapex / Revenue | 4.5% | 131.8% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-1.4B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $-572.9M | ||
| Q3 25 | $52.6M | $-114.0M | ||
| Q2 25 | $35.6M | $-231.3M | ||
| Q1 25 | $35.1M | $-122.1M | ||
| Q4 24 | $29.0M | $-255.1M | ||
| Q3 24 | $60.0M | $-56.3M | ||
| Q2 24 | $69.1M | $-42.5M | ||
| Q1 24 | $55.3M | $-57.9M |
| Q4 25 | $24.6M | $-774.3M | ||
| Q3 25 | $47.2M | $-139.7M | ||
| Q2 25 | $25.0M | $-291.7M | ||
| Q1 25 | $24.4M | $-154.9M | ||
| Q4 24 | $16.6M | $-495.4M | ||
| Q3 24 | $46.2M | $-127.6M | ||
| Q2 24 | $63.1M | $-96.1M | ||
| Q1 24 | $46.5M | $-115.2M |
| Q4 25 | 13.4% | -506.6% | ||
| Q3 25 | 24.6% | -77.5% | ||
| Q2 25 | 14.3% | -190.7% | ||
| Q1 25 | 14.3% | -96.0% | ||
| Q4 24 | 8.9% | -347.5% | ||
| Q3 24 | 24.1% | -150.5% | ||
| Q2 24 | 34.6% | -137.2% | ||
| Q1 24 | 27.1% | -145.2% |
| Q4 25 | 4.5% | 131.8% | ||
| Q3 25 | 2.8% | 14.3% | ||
| Q2 25 | 6.1% | 39.5% | ||
| Q1 25 | 6.3% | 20.4% | ||
| Q4 24 | 6.7% | 168.6% | ||
| Q3 24 | 7.2% | 84.1% | ||
| Q2 24 | 3.3% | 76.5% | ||
| Q1 24 | 5.1% | 72.3% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | -1.09× | ||
| Q2 25 | 1.15× | -1.05× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | -1.87× | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | -0.27× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
RIOT
| Bitcoin Mining Segment | $131.7M | 86% |
| Engineering Segment | $21.1M | 14% |
